EUVIMEDEUVIMED entdecken
Übersichtsarbeit

What is Optimal Neoadjuvant Therapy in HER2-Positive Breast Cancer?

Daniel S Peiffer, Caitlin Maloney, Nan Chen

Journal of the National Comprehensive Cancer Network · 2026-07 · 24 (7)

DOI: 10.6004/jnccn.2026.7047 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2026-07. Verfasst von Daniel S Peiffer und 2 weiteren Autor:innen. Beteiligte Einrichtung: 1Section of Hematology/Oncology, Department of Internal Medicine, The University of Chicago Comprehensive Cancer Center, Chicago, IL. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 109 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

HER2-positive breast cancer accounts for approximately 15%–20% of breast cancers and was historically associated with poor outcomes. The introduction of HER2-targeted therapies has significantly improved prognosis, particularly in the treatment of early-stage disease. Neoadjuvant HER2-directed therapy combined with chemotherapy is the standard of care for patients with stage II and III HER2-positive breast cancer, enabling pathologic complete response–guided treatment personalization. This review summarizes current evidence guiding the neoadjuvant management of early-stage HER2-positive breast cancer. We discuss pivotal trials establishing dual HER2 blockade with trastuzumab and pertuzumab, strategies to optimize and de-escalate chemotherapy backbones, and emerging data supporting chemotherapy-sparing approaches in selected patients. Recent studies evaluating taxane-only regimens, carboplatin omission, antibody–drug conjugates, and immunotherapy-based combinations are reviewed with attention to efficacy, toxicity, and clinical applicability. We further examine validated and emerging biomarkers of response, including molecular subtyping, genomic assays, tumor immune features, circulating tumor DNA, and functional imaging, all of which may enable risk-adapted treatment strategies. Finally, we review mechanisms of resistance to HER2-targeted therapies, as well as novel therapeutic approaches under investigation to overcome treatment resistance. This review provides a contemporary, evidence-based framework for individualized neoadjuvant treatment of early-stage HER2-positive breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleBiomarkers, TumorNeoplasm StagingTrastuzumabAntibodies, Monoclonal, Humanized

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanBiomarkers, TumorTrastuzumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • 1Section of Hematology/Oncology, Department of Internal Medicine, The University of Chicago Comprehensive Cancer Center, Chicago, IL.
  • 2Department of Internal Medicine, University of Chicago, Chicago, IL.

Zitieren

APA

Peiffer, D. S., Maloney, C., & Chen, N. (2026). What is Optimal Neoadjuvant Therapy in HER2-Positive Breast Cancer?. Journal of the National Comprehensive Cancer Network, 24(7). https://doi.org/10.6004/jnccn.2026.7047

Vancouver

Peiffer DS, Maloney C, Chen N. What is Optimal Neoadjuvant Therapy in HER2-Positive Breast Cancer?. Journal of the National Comprehensive Cancer Network. 2026;24(7). doi:10.6004/jnccn.2026.7047

BibTeX
@article{Peiffer2026,
  author = {Peiffer, Daniel S and Maloney, Caitlin and Chen, Nan},
  title = {What is Optimal Neoadjuvant Therapy in HER2-Positive Breast Cancer?},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2026},
  volume = {24},
  number = {7},
  doi = {10.6004/jnccn.2026.7047}
}
Kostenlos starten →